Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma

Cancer Science

Volumn 100, Issue 3, 2009, Pages 537-545

  Hsieh, Jeng Long ^a   Lee, Che Hsin ^b   Teo, Min Li ^b   Lin, Yih Jyh ^c   Huang, Yen Sung ^b   Wu, Chao Liang ^b   Shiau, Ai Li ^b  

^a CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; ONCOLYTIC VIRUS; PREALBUMIN; ANTINEOPLASTIC AGENT; E1A PROTEIN; E1B PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; TUMOR CELL; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; GENETICS; LIVER TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; VIROLOGY;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E1B PROTEINS; ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA, HEPATOCELLULAR; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PREALBUMIN; PROMOTER REGIONS, GENETIC;

EID: 62849119122     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01069.x     Document Type: Article

References (41)

1. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 1253-7.
2. Huang CC, Wu MC, Xu GW et al. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 1992; 84: 262-4.
3. Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
4. Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status. Gene Ther 2000; 7: 1925-9.
5. Hecht JR, Bedford R, Abbruzzese JL et al. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-61.
6. Habib N, Salama H, Abd El Latif Abu Median A et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther 2002; 9: 254-9.
7. Reid T, Galanis E, Abbruzzese J et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 2001; 8: 1618-26.
8. Reid T, Galanis E, Abbruzzese J et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-9.
9. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005; 12: 141-61.
10. Chen MJ, Green NK, Reynolds GM et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther 2004; 11: 1126-36.
11. Pei Z, Chu L, Zou W et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004; 39: 1371-81.
12. Gao Q, Zhou J, Huang X et al. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus. Mol Ther 2006; 13: 928-37.
13. Schmitz M, Graf C, Gut T et al. Melanoma cultures show different susceptibility towards E1A-, E1B-19 kDa- and fiber-modified replication-competent adenoviruses. Gene Ther 2006; 13: 893-905.
14. Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-33.
15. Li Y, Yu DC, Chen Y et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 2001; 61: 6428-36.
16. Ohashi M, Kanai F, Tateishi K et al. Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem Biophys Res Commun 2001; 282: 529-35.
17. Takahashi M, Sato T, Sagawa T et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627-34.
18. Yan C, Costa RH, Darnell JE Jr, Chen JD, Van Dyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J 1990; 9: 869-78.
19. Wakasugi S, Maeda S, Shimada K, Nakashima H, Migita S. Structural comparisons between mouse and human prealbumin. J Biochem (Tokyo) 1985; 98: 1707-14.
20. Wakasugi S, Maeda S, Shimada K. Structure and expression of the mouse prealbumin gene. J Biochem (Tokyo) 1986; 100: 49-58.
21. Costa RH, Lai E, Darnell JE Jr. Transcriptional control of the mouse prealbumin (transthyretin) gene: Both promoter sequences and a distinct enhancer are cell specific. Mol Cell Biol 1986; 6: 4697-708.
22. Tannour-Louet M, Porteu A, Vaulont S, Kahn A, Vasseur-Cognet M. A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver. Hepatology 2002; 35: 1072-81.
23. Chen SH, Hu CP, Chang CM. Hepatitis B virus replication in well differentiated mouse hepatocyte cell lines immortalized by plasmid DNA. Cancer Res 1992; 52: 1329-35.
24. Chang WH, Chen CH, Gau RJ et al. Effect of baicalein on apoptosis of the human HepG2 cell line was induced by mitochondrial dysfunction. Planta Med 2002; 68: 302-6.
25. Lin YL, Liu CC, Lei HY et al. Infection of five human liver cell lines by dengue-2 virus. J Med Virol 2000; 60: 425-31.
26. Chang FL, Lai MD. The relationship between p53 status and anticancer drugs-induced apoptosis in nine human bladder cancer cell lines. Anticancer Res 2000; 20: 351-5.
27. Hsieh JL, Wu CL, Lee CH, Shiau AL. Hepatitis B virus X protein sensitizes hepatocellular carcinoma cells to cytolysis induced by E1B-deleted adenovirus through the disruption of p53 function. Clin Cancer Res 2003; 9: 338-45.
28. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-14.
29. Shiau AL, Chen YL, Liao CY, Huang YS, Wu CL. Prothymosin alpha enhances protective immune responses induced by oral DNA vaccination against pseudorabies delivered by Salmonella choleraesuis. Vaccine 2001; 19: 3947-56.
30. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639-45.
31. Lee CH, Wu CL, Tai YS, Shiau AL. Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy. Mol Ther 2005; 11: 707-16.
32. Hsieh JL, Wu CL, Lai MD, Lee CH, Tsai CS, Shiau AL. Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5. Br J Cancer 2003; 88: 1492-9.
33. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-6.
34. Costa RH, Van Dyke TA, Yan C, Kuo F, Darnell JE Jr. Similarities in transthyretin gene expression and differences in transcription factors: liver and yolk sac compared to choroid plexus. Proc Natl Acad Sci USA 1990; 87: 6589-93.
35. O'Shea CC, Johnson L, Bagus B et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611-23.
36. Duncan S. Infection of mouse liver by human adenovirus type 5. J General Virol 1978; 40: 45-61.
37. Ganly I, Mauntner V, Balmain A. Productive replication of human adenoviruses in mouse epidermal cells. J Virol 2000; 74: 2895-9.
38. Hallden G, Hill R, Wang Y et al. Novel immunocompetent murne tumor models for the assessment of replicaiotn-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-24.
39. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971; 4: 408-11.
40. Shenk T, Flint J. Transcriptional and transforming activities of the adenovirus E1A proteins. Adv Cancer Res 1991; 57: 47-85.
41. Endo Y, Sakai R, Ouchi M et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008; 27: 2375-81.